Skip to content
Delpor.com Logo Delpor.com Logo Delpor.com Logo
  • HOME
  • ABOUT
    • Once-Yearly Therapies
    • Technology Benefits
    • Officers & Directors
    • CEO Message
  • TECHNOLOGIES
    • Summary
    • PROZORTM
    • NANOPORTM
  • DELPOR DEVICE
    • Summary
    • Comparison to Depot Formulations
    • Comparison to Other SQ Implants
  • DISEASE AREAS
    • Schizophrenia
    • Bipolar Disorder
    • Opioid Use Disorder
  • PRODUCTS
    • DLP-114
    • DLP-160
    • DLP-208
  • CONTACT
    • Contact Info
    • Corporate Development
      • Partners
      • Out-Licensing
      • Sponsored Research
      • International Partners
    • Careers
  • NEWS
  • Almost Half of Schizophrenia
    Relapses Are due to Medication
    Non-Adherence
    Imagine...
    Only Having to Take your Meds
    Once or Twice per Year
  • We are Aiming High
    Imagine...
    Once Yearly Therapies as
    the Standard Care for
    Chronic Diseases

test page

Home•test page
test pagePaul Matthew Carr2018-01-04T19:16:41+00:00

About Us

  • Once-Yearly Therapies
  • Technology Benefits
  • Officers & Directors
  • CEO Message

Technologies

  • Summary
  • ProzorTM
  • NanoporTM

Delpor’s Device

  • Summary
  • Comparison to Depot Formulations
  • Comparison to Other SQ Implants

Disease Areas

  • Schizophrenia
  • Bipolar Disorder
  • Opioid Use Disorder

Products

  • DLP-114
  • DLP-160
  • DLP-208

Partnerships

  • International Partners
  • Sponsored Research
  • Out-Licensing
  • Careers
  • Contact
© Copyright 2011 -  Delpor, Inc.  All rights reserved
Financial Conflict of Interest Policy | Website services by WebWorkz
LinkedIn
Page load link
Go to Top